{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:53:09Z","timestamp":1793451189111,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Before the introduction of new drugs, we designed a trial where treatment of newly diagnosed myeloma patients was based on the presence or absence of HLA-identical siblings. First-line treatments included a cytoreductive autograft followed by a nonmyeloablative allograft or a second melphalan-based autograft. Here, we report long-term clinical outcomes and discuss them in the light of the recent remarkable advancements in the treatment of myeloma. After a median follow-up of 7 years, median overall survival (OS) was not reached (P = .001) and event-free survival (EFS) was 2.8 years (P = .005) for 80 patients with HLA-identical siblings and 4.25 and 2.4 years for 82 without, respectively. Median OS was not reached (P = .02) and EFS was 39 months (P = .02) in the 58 patients who received a nonmyeloablative allograft whereas OS was 5.3 years and EFS 33 months in the 46 who received 2 high-dose melphalan autografts. Among patients who reached complete remission in these 2 cohorts, 53% and 19% are in continuous complete remission. Among relapsed patients rescued with \u201cnew drugs,\u201d median OS from the start of salvage therapy was not reached and was 1.7 (P = .01) years, respectively. Allografting conferred a long-term survival and disease-free advantage over standard autografting in this comparative study.<\/jats:p>","DOI":"10.1182\/blood-2011-03-339945","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T23:16:51Z","timestamp":1302736611000},"page":"6721-6727","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":107,"title":["Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma"],"prefix":"10.1182","volume":"117","author":[{"given":"Luisa","family":"Giaccone","sequence":"first","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Storer","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Clinical and Morphological Researches, University of Udine, Udine, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rotta","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sorasio","sequence":"additional","affiliation":[{"name":"Division of Hematology at the Santa Croce e Carle Hospital, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Allione","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sant'Antonio e Biagio Hospital, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Carnevale-Schianca","sequence":"additional","affiliation":[{"name":"Division of Oncology, IRCC, Candiolo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Festuccia","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Brunello","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Omed\u00e8","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Aglietta","sequence":"additional","affiliation":[{"name":"Division of Oncology, IRCC, Candiolo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Levis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sant'Antonio e Biagio Hospital, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[{"name":"Division of Hematology at the Santa Croce e Carle Hospital, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[{"name":"Division of Hematology at the Santa Croce e Carle Hospital, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Clinical and Morphological Researches, University of Udine, Udine, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannino","family":"Ciccone","sequence":"additional","affiliation":[{"name":"Unit of Cancer Epidemiology, San Giovanni Battista Hospital and CPO Piemonte, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[{"name":"Division of Hematology, San Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111711474291000_B1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111711474291000_B2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.leu.2403905","article-title":"Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.","volume":"19","author":"Bruno","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"2019111711474291000_B3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1470-2045(04)01511-6","article-title":"New drugs for treatment of multiple myeloma.","volume":"5","author":"Bruno","year":"2004","journal-title":"Lancet Oncol"},{"issue":"9023","key":"2019111711474291000_B4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","article-title":"Graft-versus-myeloma effect.","volume":"348","author":"Aschan","year":"1996","journal-title":"Lancet"},{"issue":"18","key":"2019111711474291000_B5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma.","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111711474291000_B6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres.","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111711474291000_B7","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2019111711474291000_B8","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","article-title":"Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.","volume":"89","author":"Storb","year":"1997","journal-title":"Blood"},{"issue":"11","key":"2019111711474291000_B9","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2019111711474291000_B10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111711474291000_B11","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111711474291000_B12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly-diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111711474291000_B13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"14","key":"2019111711474291000_B14","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/(SICI)1097-0258(19970730)16:14<1551::AID-SIM577>3.0.CO;2-T","article-title":"Modeling prevalence of a condition: chronic graft-versus-host disease after bone marrow transplantation.","volume":"16","author":"Couper","year":"1997","journal-title":"Stat Med"},{"issue":"29","key":"2019111711474291000_B15","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111711474291000_B16","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.","volume":"88","author":"Bj\u00f6rkstrand","year":"1996","journal-title":"Blood"},{"issue":"14","key":"2019111711474291000_B17","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2008-07-167379","article-title":"Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.","volume":"113","author":"Bruno","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2019111711474291000_B18","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2008-07-170746","article-title":"Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.","volume":"113","author":"Rotta","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111711474291000_B19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111711474291000_B20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"17","key":"2019111711474291000_B21","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111711474291000_B22","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract].","volume":"116","author":"McCarthy","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"2019111711474291000_B23","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract].","volume":"116","author":"Attal","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111711474291000_B24","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood-2008-07-168823","article-title":"Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.","volume":"112","author":"Moreau","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111711474291000_B25","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111711474291000_B26","article-title":"Donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50\/54 study [abstract].","volume":"112","author":"Lokhorst","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"2019111711474291000_B27","article-title":"Tandem autologous (ASCT)\/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT [abstract].","volume":"114","author":"Gahrton","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"2019111711474291000_B28","article-title":"Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non- myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial [abstract].","volume":"116","author":"Krishnan","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"2019111711474291000_B29","article-title":"Tandem autologous stem cell transplants (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-matched sibling non- myeloablative allogeneic stem cell transplant (auto-allo) for patients (pts) with high risk (HR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial [abstract].","volume":"116","author":"Stadtmauer","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111711474291000_B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ije\/dyg313","article-title":"Commentary: Mendelian randomization-an update on its use to evaluate allogeneic stem cell transplantation in leukaemia.","volume":"33","author":"Wheatley","year":"2004","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2019111711474291000_B31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","article-title":"Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells.","volume":"17","author":"Corradini","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111711474291000_B32","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2019111711474291000_B33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111711474291000_B34","article-title":"Molecular remission in multiple myeloma patient after a non-myeloablative allogeneic transplant: proof of principle [abstract].","volume":"98","author":"Bruno","year":"2001","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"30","key":"2019111711474291000_B35","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111711474291000_B36","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111711474291000_B37","first-page":"837","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.","volume":"91","author":"Bruno","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"2019111711474291000_B38","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-11-4449","article-title":"Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.","volume":"107","author":"van de Donk","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/24\/6721\/1340584\/zh802411006721.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/24\/6721\/1340584\/zh802411006721.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T11:47:58Z","timestamp":1573991278000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/24\/6721\/22296\/Longterm-followup-of-a-comparison-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,16]]},"references-count":38,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2011,6,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-339945","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.11379956.12395054","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,16]]}}}